Hemostasis Today

March, 2026
March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Ilenia Calcaterra: Patient-Level Real-World Outcomes of Emicizumab in Acquired Hemophilia A
Mar 7, 2026, 16:13

Ilenia Calcaterra: Patient-Level Real-World Outcomes of Emicizumab in Acquired Hemophilia A

Ilenia Calcaterra, Consultant Physician in Internal Medicine and Assistant Professor at the University of Naples Federico II, shared Emmanuel J Favaloro‘s post on LinkedIn, adding:

”Pleased to see our recent work on Emicizumab in Acquired Hemophilia A published in Seminars in Thrombosis and Hemostasis and shared by the Editor-in-Chief, Prof. Emmanuel J. Favaloro.

In this study we report real-world clinical experience and patient-level outcomes on the use of Emicizumab in a rare and complex bleeding disorder.

Our findings highlight its potential role in improving bleeding control and reducing hospitalization in selected patients with Acquired Hemophilia A.

Rare diseases require rigorous research, careful clinical judgment, and strong collaboration across centers.

Grateful to all colleagues who contributed to this work.”

Emmanuel J Favaloro, Lead Scientist at the Sydney Centres for Thrombosis and Haemostasis at Westmead Hospital, Editor in Chief of Seminars in Thrombosis and Hemostasis, shared on LinkedIn about a recent article by Ilenia Calcaterra et al, published in Seminars in Thrombosis and Hemostasis:

”Emicizumab in Acquired Hemophilia A.

Recently released online in Seminars in Thrombosis and Hemostasis.

Enjoy!”

Title: Emicizumab in Acquired Hemophilia A: A Real-World Case Series with Patient-Level Outcome Analysis

Authors: Ilenia Calcaterra, Carmine De Luca, Guido D’Errico, Ciro Miele, Chiara Caputo, Raffaele Russo, Paolo Conca, Ernesto Cimino, Anna Guida, Antonella Tufano, Matteo Di Minno

Read the Full Article on Seminars in Thrombosis and Hemostasis

Ilenia Calcaterra: Patient-Level Real-World Outcomes of Emicizumab in Acquired Hemophilia A

Stay updated on all scientific advances with Hemostasis Today.